Initial data from the core stage of a phase 2b clinical trial showed that an intranasal formulation of mebufotenin benzoate, BPL-003, significantly reduced depressive symptoms in patients with treatment-resistant depression (TRD).
Initial data from the core stage of a phase 2b clinical trial showed that an intranasal formulation of mebufotenin benzoate, BPL-003, significantly reduced depressive symptoms in patients with treatment-resistant depression (TRD).
Initial data from the core stage...